PCSK9 Revised Analysis Indicates Less Price Discounting May Be Needed

The Institute for Clinical and Economic Effectiveness’ draft cost-effectiveness report on the PCSK9 inhibitors has been updated in response to stakeholder comments and now suggests somewhat less of a price discount than originally thought necessary to allow the drugs to be considered cost-effective.

In its original draft report, released Sept. 8, ICER suggested discounts of at least 67% would be needed for Amgen Inc.’s Repatha and Sanofi and Regeneron Pharmaceuticals...